John David  Finley net worth and biography

John Finley Biography and Net Worth

CFO of Palisade Bio
Mr. Finley is an experienced financial executive having played instrumental roles in raising nearly $1 billion in capital for companies as both an internal chief financial officer (CFO) and an independent investment banker. Prior to joining Leading BioSciences as the company’s CFO, Mr. Finley was the chief executive officer, president and CFO for PointAcross, Inc., a software company providing business messaging and communications services. Mr. Finley previously co-founded Proteus Capital Partners, Inc., a firm specializing in providing financing for a variety of businesses, and was CFO at Phillips Capital, a broker/dealer firm specializing in private debt and equity capital raises. During his career, he also served as executive vice president and CFO of MetroGolf, Inc., where he successfully completed MetroGolf’s initial public offering and was instrumental in growing the start-up company to over 125 employees. Mr. Finley began his business career as a tax specialist with Deloitte & Haskins and Sells (now Deloitte LLP), and later was co-owner of Mitchell Finley & Company, a full-service accounting firm.

Mr. Finley earned a bachelor’s degree in business administration from Boise State University and a master’s degree in taxation from the University of Denver.

What is John David Finley's net worth?

The estimated net worth of John David Finley is at least $17,318.55 as of September 27th, 2023. Mr. Finley owns 43,394 shares of Palisade Bio stock worth more than $17,319 as of March 29th. This net worth estimate does not reflect any other investments that Mr. Finley may own. Learn More about John David Finley's net worth.

How do I contact John David Finley?

The corporate mailing address for Mr. Finley and other Palisade Bio executives is 20271 Goldenrod Lane, Germantown MD, 20876. Palisade Bio can also be reached via phone at (858) 704-4900 and via email at [email protected]. Learn More on John David Finley's contact information.

Has John David Finley been buying or selling shares of Palisade Bio?

John David Finley has not been actively trading shares of Palisade Bio in the last ninety days. Most recently, on Wednesday, September 27th, John David Finley bought 15,000 shares of Palisade Bio stock. The stock was acquired at an average cost of $0.54 per share, with a total value of $8,100.00. Following the completion of the transaction, the chief executive officer now directly owns 43,394 shares of the company's stock, valued at $23,432.76. Learn More on John David Finley's trading history.

Who are Palisade Bio's active insiders?

Palisade Bio's insider roster includes John Finley (CFO), Thomas Hallam (CEO), and Robert Trenschel (Director). Learn More on Palisade Bio's active insiders.

Are insiders buying or selling shares of Palisade Bio?

During the last year, Palisade Bio insiders bought shares 4 times. They purchased a total of 60,000 shares worth more than $34,800.00. During the last year, insiders at the sold shares 1 times. They sold a total of 300 shares worth more than $192.00. The most recent insider tranaction occured on January, 31st when Director Donald Allen Williams bought 10,000 shares worth more than $6,000.00. Insiders at Palisade Bio own 2.2% of the company. Learn More about insider trades at Palisade Bio.

Information on this page was last updated on 1/31/2024.

John David Finley Insider Trading History at Palisade Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/27/2023Buy15,000$0.54$8,100.0043,394View SEC Filing Icon  
9/13/2023Buy15,000$0.66$9,900.0028,394View SEC Filing Icon  
8/23/2022Buy7,350$0.16$1,176.00129,246View SEC Filing Icon  
8/16/2022Buy100,000$0.25$25,000.00121,896View SEC Filing Icon  
3/24/2022Buy7,500$1.09$8,175.00View SEC Filing Icon  
9/21/2021Buy2,000$2.44$4,880.00View SEC Filing Icon  
8/27/2021Buy10,000$2.65$26,500.00View SEC Filing Icon  
See Full Table

John David Finley Buying and Selling Activity at Palisade Bio

This chart shows John David Finley's buying and selling at Palisade Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Palisade Bio Company Overview

Palisade Bio logo
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.
Read More

Today's Range

Now: $0.40
Low: $0.39
High: $0.42

50 Day Range

MA: $0.45
Low: $0.36
High: $0.96

2 Week Range

Now: $0.40
Low: $0.36
High: $3.65

Volume

131,322 shs

Average Volume

2,689,261 shs

Market Capitalization

$3.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33